Back to search
FDAFDA · Food and drugs·Recall number D-0389-2024

Digoxin Tablets, USP 125mcg, (0.125 mg), 1000-count bottle, Rx Only, Manufactured by: Novitium Pharma LLC., 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-201-20

Published March 27, 2024 · Recall initiated: March 4, 2024

Summary

FDA records drug Class III recall D-0389-2024, published March 27, 2024 and initiated March 4, 2024. Recalling firm: Novitium Pharma LLC; Status: Terminated; Reported quantity: 3,940 1000-count bottles; Lot: Lot #: M23172A, Exp 01/31/2025. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cross Contamination with Other Products:(mycophenolate mofetil).

What to do

Voluntary: Firm initiated · Letter

Get an email if DIGOXIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DIGOXIN
Manufacturer
Novitium Pharma LLC
Distributor
Nationwide in the USA
UPC
0370954201106
Lot
Lot #: M23172A, Exp 01/31/2025
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Digoxin Tablets, USP 125mcg, (0.125 mg), 1000-count bottle, Rx Only, Manufactured by: Novitium Pharma LLC., 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-201-20 recalled?

Yes. FDA published recall D-0389-2024 on March 27, 2024. Reported hazard: Cross Contamination with Other Products:(mycophenolate mofetil).

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DIGOXIN. UPC: 0370954201106.